Literature DB >> 20664611

Measuring endogenous 5-HT release by emission tomography: promises and pitfalls.

Louise M Paterson1, Robin J Tyacke, David J Nutt, Gitte M Knudsen.   

Abstract

Molecular in vivo neuroimaging techniques can be used to measure regional changes in endogenous neurotransmitters, evoked by challenges that alter synaptic neurotransmitter concentration. This technique has most successfully been applied to the study of endogenous dopamine release using positron emission tomography, but has not yet been adequately extended to other neurotransmitter systems. This review focuses on how the technique has been applied to the study of the 5-hydroxytryptamine (5-HT) system. The principles behind visualising fluctuations in neurotransmitters are introduced, with reference to the dopaminergic system. Studies that aim to image acute, endogenous 5-HT release or depletion at 5-HT receptor targets are summarised, with particular attention to studies in humans. Radiotracers targeting the 5-HT(1A), 5-HT(2A), and 5-HT(4) receptors and the serotonin reuptake transporter have been explored for their sensitivity to 5-HT fluctuations, but with mixed outcomes; tracers for these targets cannot reliably image endogenous 5-HT in humans. Shortcomings in our basic knowledge of the mechanisms underlying changes in binding potential are addressed, and suggestions are made as to how the selection of targets, radiotracers, challenge paradigms, and experimental design might be optimised to improve our chances of successfully imaging endogenous neurotransmitters in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20664611      PMCID: PMC3023404          DOI: 10.1038/jcbfm.2010.104

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  146 in total

Review 1.  Intraneuronal trafficking of G-protein-coupled receptors in vivo.

Authors:  Véronique Bernard; Marion Décossas; Isabel Liste; Bertrand Bloch
Journal:  Trends Neurosci       Date:  2006-01-27       Impact factor: 13.837

2.  Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder.

Authors:  James W Murrough; Shannan Henry; Jian Hu; Jean-Dominique Gallezot; Beata Planeta-Wilson; John F Neumaier; Alexander Neumeister
Journal:  Psychopharmacology (Berl)       Date:  2010-05-18       Impact factor: 4.530

3.  Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain.

Authors:  S Fletcher; N M Barnes
Journal:  Brain Res       Date:  1996-08-12       Impact factor: 3.252

4.  Heterogeneity of cortical and hippocampal 5-HT1A receptors: a reappraisal of homogenate binding with 8-[3H]hydroxydipropylaminotetralin.

Authors:  E K Nénonéné; F Radja; M Carli; L Grondin; T A Reader
Journal:  J Neurochem       Date:  1994-05       Impact factor: 5.372

5.  Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants.

Authors:  S Ramamoorthy; R D Blakely
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

6.  [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia.

Authors:  P W Burnet; S L Eastwood; P J Harrison
Journal:  Neurochem Int       Date:  1997-06       Impact factor: 3.921

7.  [18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge.

Authors:  Lars H Pinborg; Karen H Adams; Stig Yndgaard; Steen G Hasselbalch; Søren Holm; Heidi Kristiansen; Olaf B Paulson; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2004-09       Impact factor: 6.200

8.  Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [(18)F] MPPF positron emission tomography study.

Authors:  Nicole Praschak-Rieder; Douglas Hussey; Alan A Wilson; Anna Carella; Maggie Lee; Edward Dunn; Matthäus Willeit; R Michael Bagby; Sylvain Houle; Jeffrey H Meyer
Journal:  Biol Psychiatry       Date:  2004-10-15       Impact factor: 13.382

9.  Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects.

Authors:  W Gordon Frankle; Raymond Y Cho; Rajesh Narendran; N Scott Mason; Shivangi Vora; Maralee Litschge; Julie C Price; David A Lewis; Chester A Mathis
Journal:  Neuropsychopharmacology       Date:  2008-07-09       Impact factor: 7.853

10.  Effect of chronic serotonin-2 receptor agonist or antagonist administration on serotonin-1A receptor sensitivity.

Authors:  J G Hensler; K A Truett
Journal:  Neuropsychopharmacology       Date:  1998-11       Impact factor: 7.853

View more
  46 in total

Review 1.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

2.  Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approach.

Authors:  Sjoerd J Finnema; Andrea Varrone; Tzung-Jeng Hwang; Christer Halldin; Lars Farde
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-14       Impact factor: 6.200

Review 3.  Quantitative Rodent Brain Receptor Imaging.

Authors:  Kristina Herfert; Julia G Mannheim; Laura Kuebler; Sabina Marciano; Mario Amend; Christoph Parl; Hanna Napieczynska; Florian M Maier; Salvador Castaneda Vega; Bernd J Pichler
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

4.  Cerebral serotonin release correlates with [11C]AZ10419369 PET measures of 5-HT1B receptor binding in the pig brain.

Authors:  Louise M Jørgensen; Pia Weikop; Claus Svarer; Ling Feng; Sune H Keller; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2017-07-07       Impact factor: 6.200

5.  Neural correlates of the popular music phenomenon: evidence from functional MRI and PET imaging.

Authors:  Qiaozhen Chen; Ying Zhang; Haifeng Hou; Fenglei Du; Shuang Wu; Lin Chen; Yehua Shen; Fangfang Chao; June-Key Chung; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-12       Impact factor: 9.236

6.  Fluctuations in [¹¹C]SB207145 PET binding associated with change in threat-related amygdala reactivity in humans.

Authors:  Patrick MacDonald Fisher; Mette Ewers Haahr; Christian Gaden Jensen; Vibe Gedsoe Frokjaer; Hartwig Roman Siebner; Gitte Moos Knudsen
Journal:  Neuropsychopharmacology       Date:  2015-01-06       Impact factor: 7.853

7.  Preclinical Evaluation of the First Adenosine A1 Receptor Partial Agonist Radioligand for Positron Emission Tomography Imaging.

Authors:  Min Guo; Zhan-Guo Gao; Ryan Tyler; Tyler Stodden; Yang Li; Joseph Ramsey; Wen-Jing Zhao; Gene-Jack Wang; Corinde E Wiers; Joanna S Fowler; Kenner C Rice; Kenneth A Jacobson; Sung Won Kim; Nora D Volkow
Journal:  J Med Chem       Date:  2018-11-13       Impact factor: 7.446

8.  5-HT1A sex based differences in Bmax, in vivo KD, and BPND in the nonhuman primate.

Authors:  Dustin W Wooten; Ansel T Hillmer; Jeffrey M Moirano; Dana L Tudorascu; Elizabeth O Ahlers; Maxim S Slesarev; Todd E Barnhart; Jogeshwar Mukherjee; Mary L Schneider; Bradley T Christian
Journal:  Neuroimage       Date:  2013-03-26       Impact factor: 6.556

9.  Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.

Authors:  Ursula F Bailer; Guido K Frank; Julie C Price; Carolyn C Meltzer; Carl Becker; Chester A Mathis; Angela Wagner; Nicole C Barbarich-Marsteller; Cinnamon S Bloss; Karen Putnam; Nicholas J Schork; Anthony Gamst; Walter H Kaye
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

Review 10.  Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans.

Authors:  Patrick M Fisher; Ahmad R Hariri
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.